OBI 833

Drug Profile

OBI 833

Alternative Names: Globo H-CRM 197; OBI-833; OBI-833/OBI-821

Latest Information Update: 20 Jan 2016

Price : $50

At a glance

  • Originator Academia Sinica
  • Developer OBI Pharma
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Dec 2015 Phase-I clinical trials in Solid tumours (Metastatic disease, Second-line therapy or greater) in Taiwan (SC)
  • 11 Dec 2014 Preclinical trials in Solid tumours in Taiwan (SC)
  • 11 Dec 2014 Optimer Biotechnology plans a phase I trial in Solid tumours (Late-stage disease, Metastatic disease) in Taiwan and USA (NCT02310464)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top